MarketPulse

Skyrizi

5 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

AbbVie Crushes Q1 Forecasts as Immunology Powerhouses Accelerate Growth Trajectory

AbbVie beats Q1 earnings with $15B revenue, accelerates $31B immunology drug guidance to 2026 from 2027. Stock down 10% YTD despite outperformance.
ABBVearningsrevenue growth
BenzingaBenzinga··Vandana Singh

AbbVie Beats Q1 Expectations on Immunology, Neuroscience Surge

AbbVie exceeded Q1 earnings expectations with $15B revenue and raised 2026 guidance, driven by strong immunology and neuroscience portfolio performance.
ABBVrevenue beatguidance raise
The Motley FoolThe Motley Fool··Thomas Niel

AbbVie's Unbroken Dividend Streak: 10+ Years of Increases Despite Patent Cliff

AbbVie maintains 10+ years of consecutive dividend increases despite Humira patent loss, buoyed by blockbuster drugs Skyrizi and Rinvoq projected to reach $50B by 2030.
ABBVABTearnings growthdividend growth
BenzingaBenzinga··Vandana Singh

J&J and Protagonist Win FDA Approval for Oral Psoriasis Drug, Challenging AbbVie's Market Dominance

FDA approves Icotyde for psoriasis, triggering $50M payment to Protagonist. Market reacts with AbbVie stock falling 5.20% amid competitive pressure.
JNJABBVPTGXFDA approvalplaque psoriasis
BenzingaBenzinga··Vandana Singh

AbbVie's Skyrizi Posts Strong Remission Data, Challenges J&J in Crohn's Market

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.
JNJABBVimmunologyCrohn's disease